NASDAQ: ENTX - Entera Bio Ltd.

Rentabilité sur six mois: -5.64%
Secteur: Healthcare

Calendrier des promotions Entera Bio Ltd.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

Plus de détails
Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.000236
EBITDA -0.0112
Число акций ао 0.02901 млрд
P/S 109.63
P/BV 2.17
EV/EBITDA -0.9795
Цена ао 1.55
ISIN IL0011429839
Сайт https://www.enterabio.com
P/E 2144.95
Валюта usd
IPO date 2018-06-28
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: -0.5405% (1.85)
Changement de prix par semaine: -4.32% (1.9231)
Changement de prix par mois: -2.13% (1.88)
Changement de prix sur 3 mois: +10.18% (1.67)
Changement de prix sur six mois: -5.64% (1.95)
Changement de prix par an: +162.48% (0.701)
Evolution du prix sur 3 ans: -62.3% (4.88)
Evolution du prix sur 5 ans: -34.29% (2.8)
Evolution des prix depuis le début de l'année: +162.86% (0.7)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 1352.38 1
P/BV 1.82 8
P/E 2144.95 1
EV/EBITDA -0.9348 0
Total: 4

Efficacité

Nom Signification Grade
ROA, % -75.55 0
ROE, % -85.59 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0439 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -94.07 0
Rentabilité Ebitda, % -20.68 0
Rentabilité EPS, % -65.78 0
Total: 0
Plus de détails

Établissements Volume Partager, %
Knoll Capital Management, LLC 3881879 10.94
TWO SIGMA SECURITIES, LLC 69441 0.2
Renaissance Technologies, LLC 57400 0.16
Geode Capital Management, LLC 17597 0.05
PNC Financial Services Group, Inc. 13000 0.04
HighTower Advisors, LLC 11830 0.03
Millennium Management LLC 10097 0.03
Morgan Stanley 1000 0
Group One Trading, L.P. 345 0
Royal Bank of Canada 200 0



Superviseur Titre d'emploi Paiement Année de naissance
Ms. Miranda J. Toledano M.B.A. CEO & Director 418k 1977 (47 années)
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer 296k 1978 (46 années)
Ms. Dana Yaacov-Garbeli CPA Chief Financial Officer 193k 1983 (41 année)
Dr. Gregory Burshtein Ph.D. Chief of Research & Development 1976 (48 années)

Adresse: Israel, Jerusalem, Kiryat Hadassah Minrav Building - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.enterabio.com